KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $340.2 million.

  • Biomarin Pharmaceutical's Free Cash Flow rose 6759.01% to $340.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $832.1 million, marking a year-over-year increase of 16013.36%. This contributed to the annual value of $487.4 million for FY2024, which is 67901.96% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Free Cash Flow of $340.2 million as of Q3 2025, which was up 6759.01% from $168.2 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Free Cash Flow high stood at $340.2 million for Q3 2025, and its period low was -$98.4 million during Q1 2023.
  • Over the past 5 years, Biomarin Pharmaceutical's median Free Cash Flow value was $78.3 million (recorded in 2021), while the average stood at $77.9 million.
  • In the last 5 years, Biomarin Pharmaceutical's Free Cash Flow crashed by 18436.79% in 2022 and then skyrocketed by 1168277.55% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Free Cash Flow (Quarter) stood at -$17.6 million in 2021, then crashed by 64.61% to -$28.9 million in 2022, then skyrocketed by 95.04% to -$1.4 million in 2023, then skyrocketed by 11682.78% to $166.1 million in 2024, then soared by 104.84% to $340.2 million in 2025.
  • Its last three reported values are $340.2 million in Q3 2025, $168.2 million for Q2 2025, and $157.6 million during Q1 2025.